1,029 reports of this reaction
4.4% of all VEMURAFENIB reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for VEMURAFENIB, manufactured by Genentech, Inc.. There are 1,029 FDA adverse event reports linking VEMURAFENIB to FATIGUE. This represents approximately 4.4% of all 23,551 adverse event reports for this drug.
Patients taking VEMURAFENIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among VEMURAFENIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for VEMURAFENIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,029 FDA reports for VEMURAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.4% of all adverse event reports for VEMURAFENIB, making it a notable side effect.
If you experience fatigue while taking VEMURAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.